Top Markets
Coin of the day
TherapeuticsMD, Inc. TherapeuticsMD, Inc.

TherapeuticsMD, Inc.

TXMD
Clasificación en acciones #28984
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to... TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Precio por acción
$2.04
Capitalización bursátil
$23.61M
Cambio (1 día)
1.49%
Cambio (1 año)
75.86%
País
US
Comercio TherapeuticsMD, Inc. (TXMD)

Categoría

Ratio P/B de TherapeuticsMD, Inc. (TXMD)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de TherapeuticsMD, Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de TherapeuticsMD, Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras